Newsletter

February 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: January Scorecard Number of Signals 11 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 6% Other stats: Number of signals over $10/share 9 Number […]

0Comments

Allakos Reports Positive Phase 1 Clinical Trial Results for AK002

On February 19, Allakos, Inc. (ALLK) announced positive Phase 1 clinical trial results for its drug AK002, which is used to treat eosinophil and mast cell related diseases. The drug is being tested on patients with indolent systemic mastocytosis (ISM), a debilitating disorder caused by the release of inflammatory mediators from mast cells, who had […]

0Comments

January 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: January Scorecard Number of Signals 10 Percent Correct – Prev Close to 5-day Peak 90% Avg Increase – Next open to 5-day Peak 8% Other stats: Number of signals over $10/share 6 Number […]

0Comments

December 2018 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: December Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 75% Avg Increase – Next open to 5-day Peak 7% Other stats: Number of signals over $10/share 12 Number […]

0Comments

November 2018 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: November Scorecard Number of Signals 8 Percent Correct – Prev Close to 5-day Peak 88% Avg Increase – Next open to 5-day Peak 8% Other stats: Number of signals over $10/share 5 Number […]

0Comments

October 2018 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: October Scorecard Number of Signals 19 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 8% Other stats: Number of signals over $10/share 13 Number […]

0Comments

September 2018 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: August Scorecard Number of Signals 49 Percent Correct – Prev Close to 5-day Peak 92% Avg Increase – Next open to 5-day Peak 11% Other stats: Number of signals over $10/share 30 Number […]

0Comments

Paratek Receives FDA Approval of NUZYRA to Treat Bacterial Pneumonia and Skin Infections

On October 2, Paratek Pharmaceuticals, Inc. (PRTK) announced that the company received FDA approval of NUZYRA™ (omadacycline) to treat community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). NUZYRA is an antibiotic that can be administered either orally or through a once-daily IV treatment. Paratek plans to have the drug available in […]

0Comments

Seattle Genetics and Takeda Pharmaceuticals Report Positive Topline Phase 3 Clinical Trial Results

On October 1, Seattle Genetics, Inc. (SGEN) and Takeda Pharmaceutical Company Limited (TSE) reported results from their phase 3 clinical trial of ECELON-2. The trial demonstrated a statistically significant improvement in progression-free survival for patients using their drug Adcentris in combination with chemotherapy when compared to chemotherapy alone. It is the first randomized Phase 3 […]

0Comments

Akcea and Ionis Announce Positive Phase 2 Clinical Trial Results

Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (IONS), announced positive topline clinical trial results on September 24. The Phase 2 clinical trial is studying the effect of AKCEA-APO(a)-LRx on patients with established cardiovascular disease and elevated levels of lipoprotein(a), known as Lp(a). The goal of the Phase 2 clinical study was to […]

0Comments

Latest of Knowledge Center